CTI BIOPHARMA CORP

Form 4 July 09, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Plunkett Matthew Issuer Symbol CTI BIOPHARMA CORP [CTIC] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner Other (specify _X__ Officer (give title 3101 WESTERN AVENUE, SUITE 07/07/2014 below) 600 EVP, Corporate Development (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting SEATTLE, WA 98121 Person

(City)	(State) (Zip) Table	e I - Non-D	erivative	Secur	ities Acqu	uired, Disposed of	f, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	, , ,			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
~			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	07/07/2014		S <u>(1)</u>	300	D	\$ 2.815	596,604	D	
Common Stock	07/07/2014		S <u>(1)</u>	500	D	\$ 2.82	596,104	D	
Common Stock	07/07/2014		S(1)	100	D	\$ 2.835	596,004	D	
Common Stock	07/07/2014		S(1)	800	D	\$ 2.84	595,204	D	
Common Stock	07/07/2014		S(1)	900	D	\$ 2.845	594,304	D	

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	07/07/2014	S <u>(1)</u>	1,000	D	\$ 2.85 593,304	D
Common Stock	07/07/2014	S <u>(1)</u>	500	D	\$ 2.855 592,804	D
Common Stock	07/07/2014	S(1)	600	D	\$ 2.86 592,204	D
Common Stock	07/07/2014	S(1)	200	D	\$ 2.865 592,004	D
Common Stock	07/07/2014	S <u>(1)</u>	600	D	\$ 2.88 591,404	D
Common Stock	07/07/2014	S <u>(1)</u>	600	D	\$ 2.9 590,804	D
Common Stock	07/07/2014	S(1)	1,700	D	\$ 2.92 589,104	D
Common Stock	07/07/2014	S <u>(1)</u>	900	D	\$ 2.925 588,204	D
Common Stock	07/07/2014	S(1)	1,700	D	\$ 2.93 586,504	D
Common Stock	07/07/2014	S(1)	600	D	\$ 2.935 585,904	D
Common Stock	07/07/2014	S(1)	200	D	\$ 2.94 585,704	D
Common Stock	07/07/2014	S <u>(1)</u>	200	D	\$ 2.955 585,504	D
Common Stock	07/07/2014	S(1)	600	D	\$ 2.96 584,904	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber		Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e	Securities	(Instr. 5)	Bene
	Derivative				Securities	S	(Instr. 3 and 4)		Owne
	Security				Acquired				Follo
					(A) or				Repo
					Disposed				Trans
					of (D)				(Instr
					(Instr. 3,				

Edgar Filing: CTI BIOPHARMA CORP - Form 4

4, and 5)

Amount Expiration Title Number Exercisable Date of Code V (A) (D) Shares

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

> > Date

Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121

EVP, Corporate Development

Signatures

Louis A. Bianco, Attorney-in-fact For: Matthew Plunkett

07/09/2014 **Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3